EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the preferred frontline therapy for EGFR-mutant advanced NSCLC. However, despite its high initial response rates, multiple EGFR-independent mechanisms of resistance have been reported in patients receiving osimertinib. One such mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: von Buttlar, Xinyu, Reuss, Joshua E., Liu, Stephen V., Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474351/
https://www.ncbi.nlm.nih.gov/pubmed/34590027
http://dx.doi.org/10.1016/j.jtocrr.2021.100179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474351/
https://www.ncbi.nlm.nih.gov/pubmed/34590027
http://dx.doi.org/10.1016/j.jtocrr.2021.100179

Ejemplares similares